Skip to main content

Table 1 Active clinical trials of novel therapeutic agents for RRMM presented at major oncology meetings, 2019–2020

From: Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Antigen

Product name* (NCT)

Study sponsor

Estimated enrollment

Country

Clinical Update reference

CAR-T cells

     

BCMA

JNJ-68284528 (NCT03548207)

Janssen

118

United States, Japan

2020 ASH [7]

BCMA

bb21217 (NCT03274219)

Bluebird

74

United States

2020 ASH [8]

NY-ESO-1

GSK3377794 (NCT03168438)

GlaxoSmithKline

20

United States

2019 ASH [9]

BCMA /CD19

GC012F (NCT04236011)

Shanghai Changzheng Hospital

15

China

2020 ASH [10]

BCMA/CD38

BM 38CAR (ChiCTR1800018143)

Wuhan Tongji Medical College Union Hospital

20

China

2019 ASH [11]

BCMA

ALLO-715 (NCT04093596)

Allogene

90

United States

2020 ASH [12]

Bispecific antibody (BiTE)

     

BCMA × CD3

Teclistamab JNJ-64007957 (NCT03145181)

Janssen

160

United States, the Netherlands, Spain, Sweden

2020 ASH [13]

BCMA × CD3

CC-93269 (NCT03486067)

Celgene

115

United States, Spain

2019 ASH [14]

BCMA × CD3

PF-06863135 (NCT03269136)

Pfizer

80

United States, Canada

2020 ASH [15]

BCMA × CD3

TNB-383B (NCT03933735)

Tenebio AbbVie

72

United States

2020 ASH [16]

BCMA × CD3

REGN5458 (NCT03761108)

Regeneron

74

United States, Belgium

2020 ASH [17]

GPRC5D × CD3

Talquetamab JNJ-64407564 (NCT03399799)

Janssen

245

United States, Netherlands, Spain

2020 ASH [18]

FcRH5 × CD3

BFCR4350A (NCT03275103)

Genentech

300

United States, Australia, Canada, Spain

2020 ASH [19]

Antibody–drug conjugate (ADC)

     

BCMA, pyrrolobenzodiazepine

MEDI2228 (NCT03489525)

MedImmune

142

United States, Australia, Greece

2020 ASH [20]

BCMA, Shiga-like toxin-A subunit (engineered toxin bodies)

TAK-169 (NCT04017130)

Millennium Takeda

102

United States

2019 ASH [21]

Monoclonal antibody (MoAb)

     

CD38

TAK-079 (NCT03439280)

Millennium Takeda

100

United States

2020 ASCO [22]

CD38 with interferon

TAK-573 (NCT03215030)

Millennium Takeda

151

United States

2020 ASH [23]

CD38

SAR442085 (NCT04000282)

Sanofi

78

United States, France, Spain

2020 AACR[24]

Small molecule inhibitors and modulators

     

BCL-2 inhibitor

Venetoclax (NCT03314181, NCT01794520)

AbbVie

104, 117

United States, Australia, Belgium, Canada, Denmark, France, Germany, Norway

2019 ASH [25], 2019 ASH [26]

BCL-2 inhibitor

AT-101 (NCT02697344)

Mayo Clinic

10

United States

2019 ASH [27]

HDAC inhibitor

Alteminostat (NCT03150316)

Chong Kun Dang Pharamaceutical

18

South Korea

2019 ASH [28]

HDAC inhibitor

Chidamide (NCT04025450)

The First Affiliated Hospital of Soochow University

50 (high-risk NDMM)

China

2019 ASH [29]

Cereblon E3 ligase modulator

Iberdomide (CC-220) (NCT02773030)

Celgene

449

United States, France, Germany, Italy, Japan, the Netherlands, Spain, United Kingdom

2020 ASH [30]

Cereblon E3 ligase modulator

CC-92480 (NCT03374085)

Celgene

80

United States, Canada, Denmark, Finland, Spain, United Kingdom

2020 ASH [31]

MEK inhibitor

Cobimetinib (NCT03312530)

Hoffmann-La Roche

72

Czechia, Denmark, France, Germany, Netherlands, Norway, Poland, Spain, Sweden

2020 ASH [32]

MEK and BRAF inhibitors

Encorafenib and binimetinib (NCT02834364)

University of Heidelberg

12

Germany

2020 ASH [33]

Other therapies

     

Peptidase enhanced cytotoxic

Melflufen (NCT03481556)

Oncopeptides

80

United States, Czechia, Spain

2020 ASH [34]

Peptidase enhanced cytotoxic

Melflufen (NCT02963493)

Oncopeptides

157

United States, France, Italy, Spain

2020 ASCO [35]

  1. ASCO American Society of Clinical Oncology, ASH American Society of Hematology, AACR American Association for Cancer Research
  2. *In cases where no unique product name was given, only the NCT number is listed to the bottom of the table (see Table 2 for example)